How to Respond to an FDA Warning Letter: The Step-by-Step Playbook for the First 15 Business Days

If you have just received an FDA warning letter - or if you want to know exactly what to do if you ever do - this is the tactical playbook. The first 15 business days after a warning letter arrives determine how the enforcement proceeds. A well-structured response can lead to closure of the matter without further escalation. A poorly-structured response, or a missed response deadline, accelerates escalation toward consent decrees, seizures, or worse. This post covers the exact sequence of actions and what each involves.

Step 1 - Call a healthcare regulatory attorney the same day

The first call is to an attorney. Not your general business lawyer unless they have specific FDA regulatory experience - the body of law, enforcement practices, and response conventions are specialized enough that a non-specialist attorney will slow the response rather than accelerate it.

What to tell the attorney

• You received an FDA warning letter.
• The general subject of the letter (marketing claims, HCT/P products, device usage, etc.).
• Whether you have made any public statement or taken any visible corrective action yet.
• Whether any staff members have been made aware or discussed it externally.

What the attorney will do first

• Review the letter and identify each cited violation and regulatory basis.
• Assess whether the facts support the cited violations or whether aspects of the letter are factually contestable.
• Advise on immediate corrective actions and on preservation of records.
• Advise on communications - with whom, through what channels, and what not to say to anyone.

Step 2 - Preserve all marketing records

Record preservation is not about hiding - it’s about making sure you have complete information to build the response. Preservation also protects against later claims that you altered or deleted evidence.

What to preserve

• Screenshots and archives of every marketing surface cited in the letter - as of the date the letter was issued.
• Full inventories of related marketing surfaces not cited - your attorney will need to understand the full pattern.
• Business records relevant to the claims - invoices, staff training materials, marketing approval logs, substantiation files if any exist.
• Communications related to the marketing - emails, Slack messages, meeting notes.

How to preserve

Work with your attorney to implement a litigation hold - a formal preservation notice to staff and vendors instructing them to preserve rather than delete relevant materials. This is standard practice in regulatory response and protects against spoliation claims.

Step 3 - Map the full scope of the letter

Before you start correcting, understand what needs to be corrected and why. A response that addresses the letter narrowly - fixing only the specific phrases cited - often fails to close the underlying pattern, which means the FDA returns later.

Building the scope map

1. Each specific citation. What phrases, which surfaces, what the FDA said about each.
2. Regulatory basis for each citation. The specific statute or regulation the FDA says was violated.
3. Evidence the FDA relied on. Usually the letter references specific content with dates - this is the evidence base.
4. Related content the FDA didn’t cite but could have. A warning letter typically catches a subset of a pattern. The full pattern needs to be addressed.
5. Corrective actions expected. What the FDA specifically asked for, plus what good-faith compliance practice would add.

Step 4 - Execute immediate corrective actions

Under attorney direction, begin implementing corrective actions on the cited content. Do not start before the scope mapping is complete - piecemeal correction creates inconsistent record trails that complicate the response.

Document everything

Every change gets documented: what was changed, when, by whom, and what replaced it. The documentation becomes part of the response package. This documentation is evidence of good-faith compliance, which affects how the FDA evaluates the response.

Correct consistently across surfaces

If the letter cites a phrase on your website, check every surface where that phrase or its variants appear. A correction that leaves the same phrase on social media, in marketing emails, or on staff bios reads as incomplete and invites follow-up.

Don’t over-correct in ways that are visible

Leaving visible “corrected at FDA request” notices across your website is generally not required and typically advised against by counsel. The correction itself is what matters; broadcasting it publicly rarely helps the response and can affect patient perception.

Step 5 - Build the structural corrective plan

The FDA does not just want surface-level corrections. It expects structural changes that prevent recurrence. This is where most responses fall short - they fix the specific phrases cited but don’t demonstrate that the practice will not make the same category of mistake next month.

Structural changes that strengthen responses

• Pre-publish compliance review. Documented process where all marketing content is reviewed before publication against a specific rule set.
• Staff training. Dated training records covering the specific rules cited in the letter plus broader compliance principles.
• Designated compliance officer. Named individual with documented responsibility and authority for marketing compliance.
• Audit schedule. Recurring audit schedule going forward, with documented audit completion.
• Vendor review process. Process for reviewing third-party marketing materials (manufacturer assets, agency deliverables) before use.

Step 6 - Submit the written response

The written response is what the FDA evaluates. Its structure matters. Your attorney drafts it, but understanding what it should contain helps you provide the right documentation.

Structure of a strong response

1. Acknowledgment.Acknowledge receipt of the letter and the seriousness of the concerns raised. Do not make admissions that your attorney hasn’t specifically advised.
2. Citation-by-citation response. Address each specific citation with the corrective action taken and the supporting documentation.
3. Structural changes. Describe the broader compliance program changes with supporting documentation.
4. Timeline. Clear timeline of when each action was taken and when each remaining action will be complete.
5. Commitment. Clear commitment to ongoing compliance with specific accountabilities.

Tone

Professional, cooperative, factual. Not defensive, not argumentative. The FDA has broad discretion in how it proceeds - a cooperative response tone affects how that discretion is exercised even when the underlying facts are contested.

The 15-day clock

The standard warning letter response window is 15 business days. Extensions are sometimes available with good cause but cannot be assumed. Build the timeline to meet the 15-day deadline from the start.

Every FDA warning letter response is its own negotiation under formal process. The outcome is not predetermined by the letter itself - it’s shaped by the quality of the response. A strong response can close a serious letter without further action; a weak response can escalate a marginal letter into significant enforcement.

After the response is submitted

Possible FDA responses

• Close-out letter. The ideal outcome - the FDA confirms corrective actions are sufficient and the matter is closed (though subject to later revisitation if violations recur).
• Follow-up questions. The FDA asks for additional information or clarification. Respond promptly under counsel guidance.
• Escalation. If the response is deemed inadequate, the FDA can escalate - consent decree, seizure, injunction, or criminal referral in severe cases.
• Silence. The FDA may simply not respond in writing. Silence is not necessarily closure - the matter remains open in principle until explicitly closed.

Ongoing compliance monitoring

After submitting the response, the practical work is ongoing: maintain the structural changes, keep the audit schedule, document new marketing through the compliance process, and preserve records. Many warning letter matters reopen based on recurrence of similar violations 6-18 months later.

Frequently asked questions

How much does a warning letter response typically cost?

Legal costs for a typical warning letter response range from $50,000 to $150,000 depending on complexity, the number of citations, and the depth of the evidentiary record. Severe matters or cases that escalate can run significantly higher.

Do I have to retain all marketing during the response?

No - cited marketing typically needs correction, not retention. But preserve the original versions for your records. Your attorney will advise on specific retention.

Should I notify patients of the warning letter?

Typically not, unless the warning letter specifically requires it or unless your attorney advises it as part of response strategy. Unnecessary patient notification can create reputation and operational issues without helping the response.

Will the warning letter be publicly searchable?

Yes. The FDA posts warning letters on its public website with a searchable database. The letter becomes a permanent public record regardless of response outcome.

Can I still operate while responding?

Yes - in most cases. A warning letter does not automatically suspend operations. It demands corrective action on specific issues, and operations continue during the response (typically with the cited issues corrected). Exceptions exist for specific enforcement types that accompany seizures or injunctions.

Does receiving one warning letter guarantee more scrutiny later?

It typically increases scrutiny, yes. Practices with a warning letter history are more likely to be reviewed if complaints are made, if similar violations are found, or if the FDA conducts routine sweeps of the practice category. Continued strict compliance is the operational response.

What happens if I just don’t respond?

Not responding to a warning letter is essentially guaranteed to accelerate enforcement. The FDA interprets non-response as non-cooperation, which typically triggers escalation to more serious enforcement mechanisms. Even a weak response is better than no response.